



# Serum sCD163 Levels Are Associated with Type 2 Diabetes Mellitus and Are Influenced by Coffee and Wine Consumption: Results of the Di@bet.es Study

Gemma Rojo-Martínez<sup>1,2\*</sup>, Elsa Maymó-Masip<sup>2,3</sup>, M. Mar Rodríguez<sup>4</sup>, Esther Solano<sup>2,3</sup>, Albert Goday<sup>5</sup>, Federico Sorriquer<sup>1,2</sup>, Sergio Valdés<sup>1,2</sup>, Felipe Javier Chaves<sup>6,2</sup>, Elías Delgado<sup>7</sup>, Natalia Colomo<sup>1,2</sup>, Pilar Hernández<sup>3</sup>, Joan Vendrell<sup>2,3</sup>, Matilde R. Chacón<sup>2,3\*</sup>

**1** UGCI de Endocrinología y Nutrición, Instituto de Biomedicina de Málaga (IBIMA), Hospital Regional Universitario, Málaga, Spain, **2** Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas CIBERDEM, Barcelona, Spain, **3** Hospital Universitari de Tarragona Joan XXIII, IISPV, Universitat Rovira i Virgili, Tarragona, Spain, **4** CIBEROBn Fisiopatología, Obesidad y Nutrición, Institut D'investigació Biomedica De Girona Dr Josep Trueta, Girona, Spain, **5** Department of Endocrinology and Nutrition Hospital del Mar, Parc de Salut Mar, Universitat Autònoma de Barcelona, Barcelona, Spain, **6** Genotyping and Genetic Diagnosis Unit, Fundación de Investigación del Hospital Clínico de Valencia-INCLIVA, Valencia, Spain, **7** Departamento de Medicina-Endocrinología y Nutrición, Hospital Universitario Central de Asturias (HUCA), Universidad de Oviedo, Oviedo, Spain

## Abstract

**Objective:** Serum levels of soluble TNF-like weak inducer of apoptosis (sTWEAK) and its scavenger receptor CD163 (sCD163) have been linked to insulin resistance. We analysed the usefulness of these cytokines as biomarkers of type 2 diabetes in a Spanish cohort, together with their relationship to food consumption in the setting of the Di@bet.es study.

**Research Design and Methods:** This is a cross-sectional, matched case-control study of 514 type 2 diabetes subjects and 517 controls with a Normal Oral Glucose Tolerance Test (NOGTT), using data from the Di@bet.es study. Study variables included clinical and demographic structured survey, food frequency questionnaire and physical examination. Serum concentrations of sTWEAK and sCD163 were measured by ELISA. Linear regression analysis determined which variables were related to sTWEAK and sCD163 levels. Logistic regression analysis was used to estimate odd ratios of presenting type 2 diabetes.

**Results:** sCD163 concentrations and sCD163/sTWEAK ratio were 11.0% and 15.0% higher, respectively, ( $P < 0.001$ ) in type 2 diabetes than in controls. Following adjustment for various confounders, the OR for presenting type 2 diabetes in subjects in the highest vs the lowest tertile of sCD163 was [(OR), 2.01 (95%CI, 1.46–2.97);  $P$  for trend  $< 0.001$ ]. Coffee and red wine consumption was negatively associated with serum levels of sCD163 ( $P = 0.0001$  and;  $P = 0.002$  for coffee and red wine intake, respectively).

**Conclusions:** High circulating levels of sCD163 are associated with type 2 diabetes in the Spanish population. The association between coffee and red wine intake and these biomarkers deserves further study to confirm its potential role in type 2 diabetes.

**Citation:** Rojo-Martínez G, Maymó-Masip E, Rodríguez MM, Solano E, Goday A, et al. (2014) Serum sCD163 Levels Are Associated with Type 2 Diabetes Mellitus and Are Influenced by Coffee and Wine Consumption: Results of the Di@bet.es Study. PLoS ONE 9(6): e101250. doi:10.1371/journal.pone.0101250

**Editor:** Sompop Bencharit, University of North Carolina at Chapel Hill, United States of America

**Received:** April 1, 2014; **Accepted:** June 4, 2014; **Published:** June 30, 2014

**Copyright:** © 2014 Rojo-Martínez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability:** The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its Supporting Information files.

**Funding:** This study was supported by projects from the Fondo de Investigación Sanitaria (FIS): PI 11/00049 (M.R.CH.), PI 11/0085 (J.V.) and PI 11/02755 (F.S.) co-financed by the European Regional Development Fund (ERDF). M.R.CH. is supported by the Research Stabilization Programme of the Instituto de Salud Carlos III (ISCIII) co-financed by Institut Català de Salut (ICS) in Catalonia. Di@bet.es study was supported by CIBER in Diabetes and Associated Metabolic Disorders - CIBERDEM (ISCIII - Ministerio de Ciencia e Innovación), Ministerio de Sanidad and Spanish Society of Diabetes - SED. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

\* Email: mrodriguez.hj23.ics@gencat.cat (MRC); gemma.rojo.m@gmail.com (GRM)

† These authors contributed equally to this work.

## Introduction

Common diabetes risk factors offer limited ability to identify subjects at risk of developing type 2 diabetes mellitus. Consequently, cross sectional epidemiological studies are being undertaken to identify new biomarkers to estimate better this risk.

Classically, inflammatory markers have been one of the most widely explored in different cohorts, but results to date are far from conclusive [1].

Recently, the inflammatory imbalance between pro-inflammatory and anti-inflammatory molecules is gaining attention as an approach to interpret a specific metabolic scenario in which a

chronic low inflammatory environment is a typical event [2] [3]. Tumor necrosis factor weak inducer of apoptosis (TWEAK), a cytokine member of the TNF- family, has emerged as a Janus-faced molecule, functioning as a pro-inflammatory cytokine in autoimmune diseases [4] [5], but with anti-inflammatory behavior in many high cardiovascular (CV) risk morbidities, such as type 2 diabetes [3] [6].

TWEAK has two protein forms, a full-length form which contains the transmembrane domain (mTWEAK), and a smaller secreted soluble form that is released into the circulation after proteolytic cleavage by a furin (sTWEAK) [7] [8]. Reduced circulating sTWEAK levels have been demonstrated in patients with type 2 diabetes suffering from chronic renal failure, and in subjects with increased atherosclerosis or type 1 diabetes [9] [10] [11] [12]. Recently, in a prospective follow-up study of a high CV risk cohort, we found that sTWEAK appears to have predictive value as a marker in the development of type 2 diabetes, highlighting a possible pathogenic role of sTWEAK in this disease [13] [14].

Circulating levels of sTWEAK could be modulated, in part, by a scavenger receptor termed CD163 (Cluster of Differentiation 163). This protein, encoded by the CD163 gene, is a member of the scavenger receptor cysteine-rich (SRCR) superfamily, and is exclusively expressed in monocytes and macrophages. CD163 is also released as a soluble form in the circulation (sCD163). It has been postulated that macrophages can recognize and internalize sTWEAK, thereby decreasing its plasma concentration [15]; although this is controversial [16]. High circulating levels of sCD163 have been linked with a more pro-inflammatory profile since it has recently been associated with long-term occurrence of type 2 diabetes in a Danish cohort, underscoring its role as a potential biomarker of diabetes [17].

Dietary-induced weight loss has been shown to modify circulating levels of sCD163 in obese patients [18]. Also, it is well known that the adherence to a healthy diet, such as Mediterranean diet and certain food consumption, are associated with an improvement in the inflammatory environment and a reduced risk of diabetes, both in prospective [19] and intervention studies [20] [21].

In view of these observations, we hypothesized that the chronic inflammatory imbalance in patients with type 2 diabetes may be linked to sCD163 and/or sTWEAK levels and in turn, this might be influenced by the type of food consumption.

We have used a wide-population based cross-sectional Spanish survey to test the concurrence of differences in circulating levels of these proteins in subjects with type 2 diabetes, exploring the influence of food consumption on plasma level variability.

## Research Design and Methods

### Study population

Cross-sectional, case-control study of 514 type 2 diabetes subjects and 517 controls (normal oral glucose tolerance test (NOGTT), namely fasting glucose <110 mg/dL and post OGTT glucose <140 mg/dL) matched by sex, age and BMI, using data from the Di@bet.es study [22]. The Di@bet.es study was a nationwide, cross-sectional, population-based survey conducted between 2009 and 2010. A cluster sampling design (100 health centers randomly selected with a probability proportional to population size) was used to select participants, forming a representative random sample of the Spanish population. For the analysis presented here, all diabetic subjects from the original Di@bet.es study were selected and matched with controls selected from the same population [23].

The study was approved by the Ethics and Clinical Investigation Committee of Hospital Regional Universitario (Malaga, Spain) in addition to other regional ethics and clinical investigation committees throughout Spain, and written informed consent was obtained from all participants.

### Variables and procedures

Participants were invited by mail and/or telephone to attend one examination visit at their health center. Information was collected using an interviewer-administered structured questionnaire, followed by a physical examination by a nurse. Fasting blood sampling and OGTT were performed.

Socio-demographic data collected included age, sex, smoking status (current smoker, ex-smoker or never smoker), and personal history of diabetes and hypertension.

Weight, height and waist and hip circumferences were measured by standardized methods [19]. The body mass index (BMI) and waist-to-hip ratio (WHR) were calculated as weight/height<sup>2</sup> (kg/m<sup>2</sup>) and waist/hip (both in cm), respectively.

Blood pressure was measured using a blood pressure monitor (Hem-703C, Omron, Barcelona, Spain) following the manufacturer's instructions. Blood pressure was measured with the subject seated and after 5 minutes of rest. Two readings were obtained and the mean value was used in the analyses.

A qualitative food frequency questionnaire (FFQ) was administered face-to-face by a trained dietitian [24]. Annual frequency consumption of 50 food items were specified in 11 different categories as follows: never/seldom, 1 and 2–3 times/month, 1, 2–3 and 4–6 times/week and 1, 2, 3, 4 and >4 times/day. For this study, food items in the FFQ were grouped in 34 categories (Table 1) and the type of oil used for either dressing, cooking, frying or making mayonnaise was queried.

Subjects with baseline capillary blood glucose levels lower than 7.8 mmol/L (140 mg/dL) and those not currently receiving treatment for diabetes underwent a standard OGTT. A venous blood sample was taken from each subject (overnight fast and post load). Samples were immediately centrifuged and stored at –18°C (15 days maximum) until shipment to the centralized CIBERDEM Biobank, where the samples were stored at –80°C for later analysis.

Serum glucose, triglycerides, and cholesterol were measured enzymatically, and HDL-Cholesterol by a direct method on an Architect C8000 Analyzer (Abbott Laboratories SA, Madrid, Spain). Serum insulin was measured by immunochemiluminescence on an Architect I8000 Analyzer (Abbott Laboratories SA). The homeostatic model assessment insulin resistance index (HOMA-IR) was calculated by the formula: (serum glucose (mmol/L) x serum insulin (mU/L))/22.5.

The diagnosis and classification of diabetes was based on plasma glucose results, using the 1999 WHO criteria [25].

Obesity was considered to be a BMI  $\geq 30$  kg/m<sup>2</sup>, and abdominal obesity a waist circumference >102 cm in men or >88 cm in women.

Hypertension was defined as ongoing antihypertensive treatment or systolic blood pressure  $\geq 140$  mmHg and/or diastolic blood pressure  $\geq 90$  mmHg.

Serum concentrations of sTWEAK and sCD163 were determined in duplicate by ELISA using the commercially available, human TWEAK/TNFSF12 kit #DY1090, and human CD163 kit #DY1607 (R&D Systems Europe, Abingdon, Oxon, UK), respectively. The intra- and inter-assay CVs were 2.5% and 7.0% for sTWEAK, and 2.4% and 6.4% for sCD163, respectively. The sensitivity of the test was of 62 pg/mL for sTWEAK and 1.56 ng/mL for sCD163.

**Table 1.** Clinical, anthropometrical and food habits of the study groups.

	<b>T2DM</b>	<b>NOGTT</b>	<b>P</b>
n	514	517	–
Age	64.9±11.7	64.9±11.8	0.9
% Men	54.5	54.5	1
BMI (kg/m <sup>2</sup> )	30.2±4.4	30.1±4.4	0.6
WHR	0.97±0.08	0.94±0.08	0.0001
SBP (mmHg)	146.4±20.0	141.2±18.4	0.0001
DBP (mmHg)	81.1±10.6	79.6±9.4	0.07
Smoking (%)	16.8	15.9	0.7
Treatment with antidiabetic drugs and/or insulin	61.6	–	–
Treatment with lipid-lowering drugs (%)	35.2	23.8	0.001
<b>Serum concentrations* :</b>			
sTWEAK (pg/mL)	645.7 (391.0–1254.2)	665.1 (425.0–1242.7)	0.8**
sCD163 (ng/mL )	181.5 (148.1–221.7)	163.5 (131.2–200.9)	0.0001**
sCD163/sTWEAK index	0.23 (0.12–0.45)	0.20 (0.12–0.37)	0.001**
HOMA-IR index	3.2 (1.9–5.1)	1.8 (1.3–2.6)	0.0001**
CRP (mg/L)	2.8 (1.3–5.2)	2.1 (1.1–4.1)	0.01**
Cholesterol mg/dL	192 (168–222)	204 (179–228 )	0.0001***
HDL-Cholesterol mg/dL	45 (38–54)	48 (42–57)	0.0001***
Triglycerides mg/dL	136 (98–202)	111 (84–146)	0.0001***
LDL-Cholesterol mg/dL	102 (82–122)	109 (93–131)	0.0001***
<b>Percentage (%) of people who take a serving at least once a day of:</b>			
Breakfast cereals	2.8	5.2	0.06
White bread	80.4	84.3	0.1
Whole bread	19.4	18.6	0.8
Sugar, honey, candy, jam and similar	25.2	67.7	<0.0001
Chocolate	6.4	12.7	0.001
Cakes, muffins and similar	27.5	36.4	0.002
Eggs	13.1	10.7	0.2
Dairy	63.7	68.2	0.1
Milkshake, pudding, custard, ice cream	6	6.2	0.8
Butter, cream, lard	3	3.2	0.9
Margarine	9.2	6.4	0.1
Salads (raw vegetables)	38.1	38.3	0.9
Vegetables as a main course or side dish	10.3	9.3	0.6
Stews with some vegetables	8.6	6.7	0.3
Potatoes	8.2	10.8	0.1
Fresh fruit and juices	81.1	84.7	0.1
Nuts	8.8	13.1	0.03
Snacks and appetizers	0.9	1.5	0.5
Meat	15.9	16.1	0.9
Sausage	14.6	11.2	0.1
Red wine	22.5	23.3	0.7
Other types of wine	5.2	6.6	0.3
Beer	9.9	11.8	0.3
Liqueurs and spirits	2.8	2.3	0.5
Any type of alcoholic beverage	33.9	39.5	0.05
Sugared soft drinks	8.2	8.4	0.9
Sugar free soda	8.4	3.8	0.002
Caffeinated coffee	41.8	48.4	0.03
Decaffeinated coffee	38.6	32.3	0.03

Table 1. Cont.

	T2DM	NOGTT	P
Tea	5.4	5.1	0.8
<b>Percentage (%) of people who take a serving at least twice a week of:</b>			
Rice, Italian pasta and similar	19.4	18.7	0.8
Pulses (lentils, beans, chickpeas)	6.4	6.9	0.7
Fresh fish and seafood	15.5	20	0.06
Canned fish and seafood	7.9	6.7	0.4
<b>Percentage (%) of people who take always olive oil for:</b>			
Seasoning	96.6	97.2	0.7
Cooking	91.4	91.9	0.8
Frying	73	76	0.2
Mayonnaise	50	49.9	0.9

\*Data are median (IQR).

\*\*Adjusted by WHR and SBP.

\*\*\*Adjusted by WHR, SBP and lipid-lowering drugs treatment.

**T2DM**; Type 2 diabetes mellitus; **NOGTT**, Normal oral glucose tolerance test; **BMI**; Body mass Index; **WHR**; Waist to hip ratio; **SBP**; Systolic Blood Pressure, **DBP**; Diastolic Blood pressure; **HOMA-IR** homeostatic model assessment insulin resistance index; **CRP**, C-reactive protein.

doi:10.1371/journal.pone.0101250.t001

Plasma concentrations of high-sensitivity C-reactive protein (CRP) was determined by a highly sensitive immunonephelometry kit (Dade Behring, Marburg, Germany). CRP cut-off value to exclude acute inflammation was 10 mg/L.

### Statistical analysis

Statistical analysis was performed using the SPSS/PC statistical package (version 19 for Windows; SPSS, Chicago, IL). For clinical and anthropometric variables, normal distributed data was expressed as mean value and SD, and for variables with no Gaussian distribution, values were expressed as median (25–75<sup>th</sup> percentile). For statistical analysis, values of variables that did not have a Gaussian distribution were logarithmically transformed.

The hypothesis testing for continuous variables was performed using t-test (or the Mann-Whitney test in the event of non-normality of distributions). Associations between the qualitative characteristics were tested by  $\chi^2$  test. Linear regression analysis was used to determine what variables were related to sTWEAK and sCD163 serum concentrations.

Logistic regression analysis was used to estimate odd ratios of presenting type 2 diabetes. Results were expressed as standardized coefficient ( $\beta$ ) and 95% confidence interval for  $\beta$  [95% CI(B)]. To evaluate dose-response relationships, *P* values for trend were calculated. In all cases the level of rejection of a null hypothesis was  $\alpha < 0.05$ .

### Results

The characteristics of the studied population are shown in Table 1. Groups were similar in age, sex ratio and BMI, however type 2 diabetes patients had higher WHR and blood pressure. Smoking habit was similar in both groups. Type 2 diabetes mellitus patients were treated with anti-diabetic drugs and/or insulin in 61.6% of cases and lipid-lowering drugs were taken by 35.2% of diabetes patients and 23.8% of NOGTT subjects. No differences were found in serum sTWEAK levels between study groups, but serum sCD163 levels, sCD163/sTWEAK index, C-reactive protein (CRP) and HOMA-IR were increased in patients with type 2 diabetes in 11.0%, 15.0%, 33.3% and 77.7% respectively, after adjusting for WHR and systolic blood pressure.

Serum lipids were different between studied groups even when adjusted by WHR, SBP and lipid-lowering drug treatment.

The association between the presence of diabetes and the frequency of intake of selected food groups was also analysed (Table 1). People with type 2 diabetes often take less cereals, sugars (honey, candy, jam and similar), chocolate, cakes, nuts, alcoholic beverages, sugared soft drinks and caffeinated coffee in general and, take more often decaffeinated coffee and sugar free soft drinks.

Spearman bivariate correlation analysis with the entire studied population showed that sTWEAK, sCD163 and sCD163/sTWEAK index were weakly and significantly related with fasting glucose ( $r = -0.08$ ,  $P < 0.01$ ;  $r = 0.13$ ,  $P < 0.001$ ; and  $r = 0.11$ ,  $P < 0.01$  respectively); WHR ( $r = -0.07$ ,  $P < 0.01$ ;  $r = 0.06$ ,  $P < 0.01$ ;  $r = 0.1$ ,  $P < 0.001$ , respectively), and HOMA-IR ( $r = -0.06$ ,  $P < 0.01$ ;  $r = 0.21$ ,  $P < 0.001$ ;  $r = 0.14$ ,  $P < 0.001$ ; respectively), although relations were direct with sCD163 and sCD163/sTWEAK index, and reverse with sTWEAK. Additionally, a weak but significantly positive relation was found between sCD163 and BMI ( $r = 0.09$ ,  $P < 0.001$ ).

Levels of sTWEAK, sCD163 and sCD163/sTWEAK index were also analyzed in relation to food intake. The intake of each food item was coded into two categories, as shown in Table 1. Univariate analysis showed that sTWEAK levels were different according to the intake of cereals, margarine and caffeinated coffee ( $P < 0.05$ , data not shown). Levels of sCD163 were different depending on the intake of olive oil, sweets, cakes, meat, canned fish, wine, coffee, eggs, butter, vegetables and legumes ( $P < 0.05$ , data not shown). The sCD163/sTWEAK index was found associated to foods in a similar manner to sCD163.

Regression analysis showed that, after adjusting for several confounding variables, caffeinated coffee and red wine intake were the only foods that remained associated solely with sCD163 ( $\beta = -0.062$ ,  $P = 0.05$  and  $\beta = -0.108$ ,  $P = 0.001$  respectively, Table 2). The association between the sCD163/sTWEAK index and HOMA-IR remained in the adjusted models ( $\beta = 0.096$ ,  $P = 0.009$ , Table 2), in contrast to that of sTWEAK or sCD163 (Table 2).

Interaction between type 2 diabetes and variables shown in Table 2 was not significant, thus the major associations with the

included variables were reported in Table 3. We found that sTWEAK levels were not different according to sex, BMI, abdominal obesity or high blood pressure presence; neither were they different with respect to coffee, decaffeinated coffee or red wine intake, but sTWEAK levels were moderately increased in non-smoking subjects.

However, sCD163 was significantly increased in women, in subjects with BMI  $\geq 30$ , abdominal obesity, high blood pressure and with active smoking status, and decreased in subjects taking caffeinated coffee or red wine at least once per day. The sCD163/sTWEAK index was increased in people with abdominal obesity, but did not change with any other variable.

In the multivariate analysis, to calculate the likelihood of having diabetes adjusted by abdominal obesity, high blood pressure, and coffee and red wine intake (logistic regression, Table 4), subjects with serum values of sCD163 in tertile 3 had twice the risk of diabetes compared with subjects with serum values in the lower tertile 1 ( $P$  for trend  $\leq 0.0001$ ). However, lower circulating levels of sTWEAK were not associated with the presence of diabetes ( $P$  for trend = 0.1), but sTWEAK tertile 2 with respect to tertile 1 were found associated; this data is not considered of importance since tertile 3 versus tertile 1 is not associated. Smoking did not alter the results (data not shown).

## Discussion

In this study we report that circulating levels of sCD163 are associated with type 2 diabetes in a Spanish population and these levels may be influenced by coffee and red wine consumption.

Several epidemiological studies have associated inflammation to type 2 diabetes [26] [27]. Elevated levels of clinical markers and inflammation mediators may be reduced after intensive life-style modifications. Furthermore, experimental data showing a link between insulin resistance and different inflammatory candidates have suggested that inflammation is intimately involved in the pathogenesis of type 2 diabetes. Accordingly, the search for useful serum biomarkers remains a major focus in many epidemiological studies. Recently, circulating soluble levels of sCD163 have been linked to long-term onset of type 2 diabetes in a Danish cohort, proposing its clinical utility as a biomarker of diabetes [17]. Previous data on obesity, a condition usually linked with insulin-resistance and low chronic inflammation, revealed that circulating levels of sCD163 mirrored particular inflammatory markers such

as CRP and TNF $\alpha$  [28]. Consistent with these findings, a close relationship between sCD163 and BMI, WHR and HOMA-IR was demonstrated in our study cohort. Furthermore, a positive association with CRP was detected also in our study. Thus, high circulating levels of sCD163 were associated with a higher prevalence of type 2 diabetes in this Spanish population. Nevertheless, sTWEAK levels were not linked with a protective cardiovascular profile in this study. Generally, studies conducted in high CV risk populations indicate that low levels of sTWEAK may point to a worse scenario [11]. A recent study highlighted the relevance of decreased serum sTWEAK as a predictive marker of type 2 diabetes. Interestingly this study was conducted in a high CV risk population, in which the incidence of type 2 diabetes was assessed during a follow up [13]. In this large prospective nested case-control study, lower sTWEAK serum levels were found in incident cases compared to matched controls. Indeed, previous cross-sectional studies have also proposed a link between sTWEAK concentration and type 2 diabetes [10]. However, in our case-control study, we did not find a clear association of sTWEAK and the presence of type 2 diabetes. Differences between studies could be explained by differences in cohort definitions. Our subjects came from a random general population without bias for any special cardiovascular risk factor. This may have reduced the power of sTWEAK as a useful biomarker, as was proposed in previous reports. Of note, we cannot discard a potential effect of this cytokine in type 2 diabetes because of the inherent limitation of a cross-sectional design. We are aware that a prospective follow-up study would be more appropriate to unequivocally confer or deny a role in type 2 diabetes occurrence, but the data presented in this work tempers the usefulness of sTWEAK as a biomarker of type 2 diabetes in a general population.

With respect to dietary habits, we have observed a strong inverse relationship between sCD163 levels and some foods typically associated with a reduced risk of diabetes, such as coffee and red wine. Although we did not find a direct association between sCD163 and type 2 diabetes, it is well known that diet might have important effects on mediators of inflammation [29] [30]. Consequently, our results provide the first indication for an inverse relationship between coffee and red wine and circulating levels of sCD163. These data are compatible with the available reports describing the beneficial effect of moderate consumption of

**Table 2.** Relationship of sCD163, sTWEAK and sCD163/sTWEAK index with caffeinated coffee and red wine.

	Log sTWEAK		Log sCD163		Log sCD163/sTWEAK index	
	Standardized $\beta$ coefficient	p	Standardized $\beta$ coefficient	p	Standardized $\beta$ coefficient	p
Sex	0.054	0.1	0.077	0.04	-0.015	0.6
Age	-0.018	0.6	0.020	0.5	0.019	0.5
Coffee intake	-0.024	0.4	-0.062	0.05	-0.031	0.3
Red wine intake	-0.013	0.6	-0.108	0.001	-0.036	0.2
WHR	-0.036	0.3	0.072	0.05	0.061	0.1
SBP	0.001	0.9	-0.008	0.8	-0.007	0.8
Diabetes presence	-0.001	0.9	0.094	0.006	0.067	0.05
Log_HOMA-IR	-0.050	0.1	0.054	0.1	0.096	0.009
Log_CRP	0.002	0.9	0.06	0.06	0.02	0.5
R <sup>2</sup> of the adjusted model	0.01	0.3	0.06	0.001	0.03	0.001

doi:10.1371/journal.pone.0101250.t002

**Table 3.** Serum concentrations of sTWEAK, sCD163 and sCD163/sTWEAK index according to characteristics of the studied subjects.

	TWEAK pg/ml	CD163 ng/ml	sCD163/sTWEAK index
<b>Men</b>	603.8 (392.8–1236.7)	166.7 (133.2–205.7)	0.21(0.13–0.41)
<b>Women</b>	726.5(429.5–1266.6)	179.2(144.6–216.1)	0.22(0.13–0.41)
<i>p</i>	0.1	0.001	0.8
<b>BMI&lt;30</b>	663.0(404.3–1247.4)	167.8(134.3–203.9)	0.21(0.13–0.40)
<b>BMI≥30</b>	648.2(407.5–1251.4)	179.6(142.3–220.0)	0.22(0.13–0.43)
<i>p</i>	0.9	0.0001	0.07
<b>Abdominal obesity (sex adjusted)</b>			
<b>No</b>	585.9(400.6–1238.3)	163.5(129.8–199.6)	0.21(0.13–0.39)
<b>Yes</b>	693.5(411.4–1251.4)	180.4(145.5–220.6)	0.22(0.13–0.43)
<i>p</i>	0.3	0.0001	0.04
<b>High blood pressure</b>	612.4(406.0–1232.9)	166.3(133.2–203.0)	0.22(0.13–0.40)
<b>No high blood pressure</b>	672.1(405.1–1254.7)	175.5(139.5–213.5)	0.22(0.13–0.42)
<i>p</i>	0.6	0.01	0.5
<b>Smoking</b>	610.2(392.2–1160.8)	162.0(126.7–196.6)	0.21(0.13–0.40)
<b>No smoking</b>	673.3(409.7–1258.6)	175.2(140.4–213.1)	0.22(0.13–0.41)
<i>p</i>	0.05	0.001	0.7
<b>Coffee less than one cup per day</b>	788.2(406.6–1290.1)	179.4(142.3–221.1)	0.21(0.13–0.41)
<b>Coffee at least one cup per day</b>	578.0(404.9–1196.5)	166.0(133.0–203.1)	0.22(0.13–0.41)
<i>p</i>	0.07	0.0001	0.9
<b>Decaffeinated coffee less than one cup per day</b>	665.2(406.3–1266.3)	170.4(138.0–208.4)	0.21(0.13–0.41)
<b>Decaffeinated coffee one or more cups per day</b>	661.2(404.3–1237.7)	177.2(139.1–216.3)	0.24(0.13–0.41)
<i>p</i>	0.1	0.1	0.7
<b>Red wine less than one drink per day</b>	658.7(410.9–1255.2)	175.4(140.6–215.9)	0.23(0.13–0.41)
<b>Red wine one or more drinks per day</b>	703.2(383.7–1242.5)	164.0(129.7–201.2)	0.19(0.13–0.40)
<i>p</i>	0.5	0.002	0.07

doi:10.1371/journal.pone.0101250.t003

coffee and wine in delaying the onset of type 2 diabetes; however, no causal effect can be inferred from the study design. [31]. Epidemiologic studies have consistently linked coffee consumption with a lower risk of type 2 diabetes [32]. In human trials, consumption of eight cups of coffee per day significantly decreases

plasma levels of proinflammatory cytokines such as IL-18, together with significant increases in adiponectin levels [33]. Similarly, coffee consumption has been inversely associated with markers of inflammation and endothelial dysfunction both in healthy women and those with type 2 diabetes [34]. Experimental data in a mouse

**Table 4.** Likelihood of having diabetes (T2DM = 1; control = 0) according to selected variables of interest.

	<i>P</i> -value	OR	95% CI of OR		<i>P</i> -for trend
			Low	High	
<b>One or more cups of caffeinated coffee per day</b>	0.1	1.19	0.91	1.56	
<b>One or more drinks of red wine per day</b>	0.3	1.17	0.86	1.59	
<b>sTWEAK tertile 1 (&lt;448 pg/mL. reference)</b>		1			
<b>sTWEAK tertile 2 (449–1040 pg/mL)</b>	0.04	0.72	0.52	0.99	0.1
<b>sTWEAK tertile 3 (&gt;1041 pg/mL)</b>	0.1	0.77	0.56	1.06	
<b>sCD163 tertile 1 (&lt;149 ng/mL. reference)</b>		1			
<b>sCD163 tertile 2 (150–197 ng/mL)</b>	0.008	1.52	1.11	2.09	≤0.001
<b>sCD163 tertile 3 (&gt;197 ng/mL)</b>	0.0001	2.01	1.46	2.77	
<b>Abdominal obesity</b>	0.0001	2.06	1.58	2.69	
<b>High blood pressure</b>	0.0001	1.71	1.26	2.31	

CI: confidence interval; OR: odds ratio.  
doi:10.1371/journal.pone.0101250.t004



model of diabetes also confirm a suppressive effect of coffee consumption on hyperglycemia, by improving insulin sensitivity in part due to reducing inflammatory cytokine expression and decreasing fat liver accumulation [35]. Caffeine has multiple actions on physiology, including inhibition of the DNA damage response, and its metabolites 1-methylxanthine and 1-methyluric acid are potent antioxidants [36]. However, the effects of caffeine on sCD163 release have not yet been investigated.

Equally, a negative association was also observed between sCD163 levels and red wine consumption. A recent study has shown that the Mediterranean diet, rich in polyphenols, reduces the incidence of type 2 diabetes [37]. In vitro, wine polyphenols, particularly the flavonoids procyanidins from grape reduces expression of pro-inflammatory cytokines such as MCP-1, IL-6 and TNF- $\alpha$  by inhibiting NF- $\kappa$ B nuclear translocation [38]. Notwithstanding the results observed, we should highlight that the frequency nutritional survey was not quantitative; therefore, we cannot measure whether these effects are due to the amount of caffeine or other active compounds in foods.

We found reduced levels of circulating sTWEAK and sCD163 in smokers. These data corroborate our previous findings on sTWEAK in smokers [13]. The potential influence of smoking on sTWEAK levels appears to be a complex issue that remains to be fully elucidated. Unexpectedly, levels of sCD163 were also found to be reduced in smokers compared with non-smokers. Data concerning the effect of smoking on inflammation appears to be contradictory; whilst cigarette smoke has been associated with oxidative stress and an inflammatory response [39], others have reported that nicotine, a major constituent of tobacco smoke, exerts anti-inflammatory effects on different cell types and appears

to be beneficial in disorders where inflammation-related mechanisms are involved, including ulcerative colitis and obesity [40] [41].

In summary, the data presented here provide new evidence for the participation of sCD163/sTWEAK binomial on the prevalence of type 2 diabetes in the general population. Furthermore, food consumption may influence the circulatory cytokine profile related to sCD163, as coffee and red wine associated with a more anti-inflammatory profile. New prospective studies are required to confirm the pathogenic link between these associations.

## Acknowledgments

We wish to acknowledge the kind collaboration of the people who voluntarily participated in the study, and to the Di@bet.es study Steering Committee that is formed by the following researchers: Federico Soriguier (coordinator), Luis Castaño, Albert Goday, Miguel Catalá, Alfonso Calle-Pascual, Gemma Rojo-Martínez, Ramón Gomís, Rafael Carmena, Manuel Serrano-Rios, Alfonso López-Alba, Inmaculada Mora-Peces, Conxa Castell, Elias Delgado, Edelmiro Menéndez, Josep Franch, José A. Vázquez, Sonia Gaztambide, Juan Girbés, Sergio Valdés, Emilio Ortega, Roser Casamitjana and Joan Vendrell.

## Author Contributions

Conceived and designed the experiments: AG ES FS SV FJC ED NC. Performed the experiments: EMM MMR. Analyzed the data: GRM MRC JV PH. Contributed reagents/materials/analysis tools: MRC GRM. Contributed to the writing of the manuscript: MRC GRM JV.

## References

- Wang X, Bao W, Liu J, Ouyang Y-Y, Wang D, et al. (2013) Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. *Diabetes care* 36: 166–175. Available: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3526249&tool=pmcentrez&rendertype=abstract>. Accessed 9 February 2014.
- Vendrell J, Maymó-Masip E, Tinahones F, García-España A, Megia A, et al. (2010) Tumor necrosis-like weak inducer of apoptosis as a proinflammatory cytokine in human adipocyte cells: up-regulation in severe obesity is mediated by inflammation but not hypoxia. *The Journal of clinical endocrinology and metabolism* 95: 2983–2992. Available: <http://www.ncbi.nlm.nih.gov/pubmed/20382683>. Accessed 18 February 2014.
- Maymó-Masip E, Fernández-Veledo S, García España A, Vázquez-Carballo A, Tinahones FJ, et al. (2013) The rise of soluble TWEAK levels in severely obese subjects after bariatric surgery may affect adipocyte-cytokine production induced by TNF $\alpha$ . *The Journal of clinical endocrinology and metabolism* 98: E1323–33. Available: <http://www.ncbi.nlm.nih.gov/pubmed/23783093>. Accessed 18 February 2014.
- Dharmapathi AaSSK, Smith MD, Crotti TN, Holding Ca, Vincent C, et al. (2011) TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis. *Arthritis research & therapy* 13: R51. Available: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3132040&tool=pmcentrez&rendertype=abstract>. Accessed 18 February 2014.
- Michaelson JS, Wisniacki N, Burkly LC, Putterman C (2012) Role of TWEAK in lupus nephritis: a bench-to-bedside review. *Journal of autoimmunity* 39: 130–142. Available: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3428508&tool=pmcentrez&rendertype=abstract>. Accessed 10 February 2014.
- Vázquez-Carballo A, Ceperuelo-Mallafre V, Chacón MR, Maymó-Masip E, Lorenzo M, et al. (2013) TWEAK prevents TNF- $\alpha$ -induced insulin resistance through PP2A activation in human adipocytes. *American journal of physiology Endocrinology and metabolism* 305: E101–12. Available: <http://www.ncbi.nlm.nih.gov/pubmed/23651848>. Accessed 18 February 2014.
- Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS (2007) TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. *Cytokine* 40: 1–16. Available: <http://www.ncbi.nlm.nih.gov/pubmed/17981048>. Accessed 24 January 2014.
- Winkles JA (2011) and therapeutic targeting. 7: 411–425. doi:10.1038/nrd2488. The.
- Yilmaz MI, Carrero JJ, Ortiz A, Martín-Ventura JL, Sonmez A, et al. (2009) Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. *Clinical journal of the American Society of Nephrology: CJASN* 4: 1716–1723. Available: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2774962&tool=pmcentrez&rendertype=abstract>. Accessed 18 February 2014.
- Kralisch S, Ziegelmeier M, Bachmann A, Seeger J, Lössner U, et al. (2008) Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. *Atherosclerosis* 199: 440–444. Available: <http://www.ncbi.nlm.nih.gov/pubmed/18054361>. Accessed 18 February 2014.
- Blanco-Colio LM, Martín-Ventura JL, Muñoz-García B, Orbe J, Páramo Ja, et al. (2007) Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. *Arteriosclerosis, thrombosis, and vascular biology* 27: 916–922. Available: <http://www.ncbi.nlm.nih.gov/pubmed/17272745>. Accessed 18 February 2014.
- Llauradó G, González-Clemente J-M, Maymó-Masip E, Subías D, Vendrell J, et al. (2012) Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. a case-control study. *PLoS one* 7: e43919. Available: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3427173&tool=pmcentrez&rendertype=abstract>. Accessed 18 February 2014.
- Díaz-López A, Chacón MR, Bulló M, Maymó-Masip E, Martínez-González Ma, et al. (2013) Serum sTWEAK concentrations and risk of developing type 2 diabetes in a high cardiovascular risk population: a nested case-control study. *The Journal of clinical endocrinology and metabolism* 98: 3482–3490. Available: <http://www.ncbi.nlm.nih.gov/pubmed/23760626>. Accessed 18 February 2014.
- Díaz-López A, Bulló M, Chacón MR, Estruch R, Vendrell J, et al. (2014) Reduced circulating sTWEAK levels are associated with metabolic syndrome in elderly individuals at high cardiovascular risk. *Cardiovascular diabetology* 13: 51. Available: <http://www.ncbi.nlm.nih.gov/pubmed/24565471>. Accessed 3 March 2014.
- Moreno Ja, Muñoz-García B, Martín-Ventura JL, Madrigal-Matute J, Orbe J, et al. (2009) The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. *Atherosclerosis* 207: 103–110. Available: <http://www.ncbi.nlm.nih.gov/pubmed/19473660>. Accessed 18 February 2014.
- Fick A, Lang I, Schäfer V, Seher A, Trebing J, et al. (2012) Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14). *The Journal of biological chemistry* 287: 484–495. Available: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3249102&tool=pmcentrez&rendertype=abstract>. Accessed 18 February 2014.
- Moller HJ, Frikke-Schmidt R, Moestrup SK, Nordestgaard BG, Tybjaerg-Hansen A (2011) Serum soluble CD163 predicts risk of type 2 diabetes in the

- general population. *Clinical chemistry* 57: 291–297. Available: <http://www.ncbi.nlm.nih.gov/pubmed/21106861>. Accessed 18 February 2014.
18. Fjeldborg K, Christiansen T, Bennetzen M, Møller JH, Pedersen SB, et al. (2013) The Macrophage-Specific Serum Marker, Soluble CD163, Is Increased in Obesity and Reduced After Dietary-Induced Weight Loss. *Obesity* 21: 2437–2443. Available: <http://dx.doi.org/10.1002/oby.20376>.
  19. Martínez-González Ma, de la Fuente-Arrillaga C, Nunez-Cordoba JM, Basterra-Gortari FJ, Beunza JJ, et al. (2008) Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study. *BMJ (Clinical research ed)* 336: 1348–1351. Available: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2427084&tool=pmcentrez&rendertype=abstract>. Accessed 29 January 2014.
  20. A IONZ (2011) Reduction in the Incidence of Type 2 Diabetes With the Mediterranean Diet Results of the PREDIMED-Reus nutrition intervention randomized trial. 34. doi:10.2337/dc10-1288.
  21. Estruher R (2010) Anti-inflammatory effects of the Mediterranean diet: the experience of the PREDIMED study. *The Proceedings of the Nutrition Society* 69: 333–340. Available: <http://www.ncbi.nlm.nih.gov/pubmed/20515519>. Accessed 5 February 2014.
  22. Soriguer F, Goday a, Bosch-Comas a, Bordiú E, Calle-Pascual a, et al. (2012) Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study. *Diabetologia* 55: 88–93. Available: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3228950&tool=pmcentrez&rendertype=abstract>. Accessed 14 February 2014.
  23. Soriguer F, Goday a, Bosch-Comas a, Bordiú E, Calle-Pascual a, et al. (2012) Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study. *Diabetologia* 55: 88–93. Available: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3228950&tool=pmcentrez&rendertype=abstract>. Accessed 29 March 2014.
  24. Ortega E, Franch J, Castell C, Goday A, Ribas-Barba L, et al. (2013) Mediterranean Diet Adherence in Individuals with Prediabetes and Unknown Diabetes: The Di@bet.es Study. *Annals of Nutrition and Metabolism* 62: 339–346. Available: <http://www.karger.com/DOI/10.1159/000346553>.
  25. Alberti KGZP (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 7: 539–553.
  26. Spranger J, Kroke A, Mo M, Hoffmann K, Bergmann MM (2003) Inflammatory Cytokines and the Risk to Develop Type 2 Diabetes. 52.
  27. Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. *Nature reviews Immunology* 11: 98–107. Available: <http://www.ncbi.nlm.nih.gov/pubmed/21233852>. Accessed 21 January 2014.
  28. Zanni M V, Burdo TH, Makimura H, Williams KC, Grinspoon SK (2012) Relationship between monocyte/macrophage activation marker soluble CD163 and insulin resistance in obese and normal-weight subjects. *Clinical endocrinology* 77: 385–390. Available: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3660104&tool=pmcentrez&rendertype=abstract>. Accessed 18 February 2014.
  29. Meksawan K, Venkatraman JT, Awad ABPD (2004) Effect of dietary fat intake and exercise on inflammatory mediators of the immune system in sedentary men and women. *J Am Coll Nutr* 4: 331–340.
  30. Richard C, Couture P, Desroches S, Lamarche B (2013) Effect of the mediterranean diet with and without weight loss on markers of inflammation in men with metabolic syndrome. *Obesity* 21: 51–57. Available: <http://dx.doi.org/10.1002/oby.20239>.
  31. Rebello Sa, Chen CH, Naidoo N, Xu W, Lee J, et al. (2011) Coffee and tea consumption in relation to inflammation and basal glucose metabolism in a multi-ethnic Asian population: a cross-sectional study. *Nutrition journal* 10: 61. Available: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3130641&tool=pmcentrez&rendertype=abstract>. Accessed 4 February 2014.
  32. Hu FB (2014) Coffee Consumption A Systematic Review. 294: 97–104.
  33. Kempf K, Herder C, Erlund I, Kolb H, Martin S, et al. (2010) Effects of coffee consumption on subclinical inflammation and other risk factors for type 2 diabetes: a clinical trial 1–3: 950–957. doi:10.3945/ajcn.2009.28548. INTRODUCTION.
  34. Lopez-Garcia E, van Dam RM, Qi L, Hu FB (2006) Coffee consumption and markers of inflammation and endothelial dysfunction in healthy and diabetic women. *The American journal of clinical nutrition* 84: 888–893. Available: <http://www.ncbi.nlm.nih.gov/pubmed/17023717>.
  35. Yamauchi R, Kobayashi M, Matsuda Y, Ojika M, Shigeoka S, et al. (2010) Coffee and caffeine ameliorate hyperglycemia, fatty liver, and inflammatory adipocytokine expression in spontaneously diabetic KK-Ay mice. *Journal of agricultural and food chemistry* 58: 5597–5603. Available: <http://www.ncbi.nlm.nih.gov/pubmed/20405946>. Accessed 24 January 2014.
  36. Mercer JR, Gray K, Figg N, Kumar S, Bennett MR (2012) The methyl xanthine caffeine inhibits DNA damage signaling and reactive species and reduces atherosclerosis in ApoE(–/–) mice. *Arteriosclerosis, thrombosis, and vascular biology* 32: 2461–2467. Available: <http://www.ncbi.nlm.nih.gov/pubmed/22859494>. Accessed 18 February 2014.
  37. A IONZ (2011) Reduction in the Incidence of Type 2 Diabetes With the Mediterranean Diet Results of the PREDIMED-Reus nutrition intervention randomized trial. 34. doi:10.2337/dc10-1288.
  38. Chacón MR, Richart C, Gómez JM, Megía a, Vilarrasa N, et al. (2006) Expression of TWEAK and its receptor Fn14 in human subcutaneous adipose tissue. Relationship with other inflammatory cytokines in obesity. *Cytokine* 33: 129–137. Available: <http://www.ncbi.nlm.nih.gov/pubmed/16503147>. Accessed 18 February 2014.
  39. Gonçalves RB, Coletta RD, Silvério KG, Benevides L, Casati MZ, et al. (2011) Impact of smoking on inflammation: overview of molecular mechanisms. *Inflammation research: official journal of the European Histamine Research Society. [et al]* 60: 409–424. Available: <http://www.ncbi.nlm.nih.gov/pubmed/21298317>. Accessed 13 February 2014.
  40. Jamal Uddin M, Joe Y, Zheng M, Blackshear PJ, Ryter SW, et al. (2013) A functional link between heme oxygenase-1 and tristetraprolin in the anti-inflammatory effects of nicotine. *Free radical biology & medicine* 65: 1331–1339. Available: <http://www.ncbi.nlm.nih.gov/pubmed/24095726>. Accessed 26 January 2014.
  41. Lakhani SE, Kirchgessner A (2011) Anti-inflammatory effects of nicotine in obesity and ulcerative colitis. *Journal of translational medicine* 9: 129. Available: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3163205&tool=pmcentrez&rendertype=abstract>. Accessed 14 February 2014.